uniQure N.V. (NASDAQ:QURE) on Friday announced updated preliminary safety and exploratory efficacy data from 11 patients in its Phase 1/2a trial of AMT-191.The updated data was presented at the WORLDSymposium in San Diego, California.Trial DataAMT-191 is an investigational AAV gene therapy under development for Fabry disease, a rare X-linked lysosomal disorder that results in excessive deposition of lipids in the tissues.As of the January 8, 2026, study data cutoff date, all 11 patients in the three dose co ...

Behind the household COVID-19 name, Moderna, is facing a $5 billion patent-infringement lawsuit over vaccine technology. On February 2, 2026, U.S. District Judge Joshua D. Wolson denied Moderna’s request for summary judgment, saying the jury will have the choice whether Moderna’s COVID-19 vaccine, Spikevax, breached on ‘lipid nanoparticle (LNP) technology’ originally patented by Genevant Sciences and Arbutus Biopharma. Judge Wolson used a “Star Trek” metaphor, saying that even with the US Government’s “ ...

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Mereo securities between June 5, 2023 and December 26, 2025, both ...

Company Overview - Gossamer Bio Inc. (NASDAQ:GOSS) is a pharmaceutical company focused on the discovery, development, and marketing of treatments in the fields of immunology, inflammation, and oncology [3]. Investment Ratings - H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Gossamer Bio and set a price target of $10 for the stock [1]. - Barclays initiated coverage on Gossamer Bio with an Overweight rating and a price target of $9, highlighting that biotech stocks like Gossamer Bio are undervalued and could benefit from ongoing mergers and acquisitions [1]. - Cantor Fitzgerald also maintains an Overweight rating on Gossamer Bio, with expectations for results from its clinical trial of seralutinib in pulmonary arterial hypertension to be released in mid to late February [2]. Clinical Trials and Data - Gossamer Bio is expected to present additional imaging data related to its clinical trials in the second quarter of 2026 [2].

SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) securities between April 1, 2024 and December 16, 2025, inclusive (the “Class Period”). The lawsuit seeks to recover losses for investors under the federal securities laws. What if I purchased Vistagen Therapeutics securities?If you purchased Vistagen Therapeutics securities during the Clas ...

Biogen (NasdaqGS:BIIB) Q4 2025 Earnings call February 06, 2026 08:30 AM ET Company ParticipantsChristopher A. Viehbacher - President and CEOPriya Singhal - Head of DevelopmentRobin C. Kramer - EVP and CFOTim Power - Head of Investor RelationsUmer Raffat - Senior Managing DirectorOperatorGood morning, my name is Ruth and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen fourth quarter and full year 2025 earnings call and business update. All lines have bee ...

Biogen (NasdaqGS:BIIB) Q4 2025 Earnings call February 06, 2026 08:30 AM ET Company ParticipantsAlexandria Hammond - Director and Head of TherapeuticsBrian Abrahams - Managing Director and Co-Head of Biotechnology ResearchChris Schott - Managing DirectorChristopher A. Viehbacher - President and CEODanielle Brill - Managing DirectorEvan David Seigerman - Managing Director and Head of Healthcare ResearchMike Yee - Global Head of Biotechnology ResearchPriya Singhal - Head of DevelopmentRobin C. Kramer - EVP and ...

Biogen (NasdaqGS:BIIB) Q4 2025 Earnings call February 06, 2026 08:30 AM ET Speaker1Good morning, my name is Ruth and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen fourth quarter and full year 2025 earnings call and business update. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star 1 on your ...

North Bergen, New Jersey--(Newsfile Corp. - February 6, 2026) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company), announces that the 'Exclusive Distribution Agreement' dated July 1, 2025, between Evolutionary Biologics (a wholly owned subsidiary of Apollo Biowellness) and Revive Regenerative, Inc. ("Revive") has been "terminated for cause" by Evolutionary Biologics, for reasons already disclosed to Revive Regenerative, Inc. and is no longer in effect.To view an enhanced version of this graphic, please ...

Woburn, Massachusetts--(Newsfile Corp. - February 6, 2026) - iSpecimen Inc. (NASDAQ: ISPC) today announced the successful completion of Milestone 2, System Integration and Marketplace Activation, marking a pivotal step in the SalesStack digital transformation journey. The milestone delivers a fully integrated, live marketplace that connects customer requests with supplier inventories, enabling streamlined operations, reduced costs, and a foundation for future growth.Chief Executive Officer Ms. Katie Field ...